Partners and Sponsors & Exhibitors

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and digital technologies to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

Regeneron and Sanofi have collaborated since 2007 to develop fully-human monoclonal antibodies for the treatment of serious diseases, including cancer. Together, they are committed to advancing therapies that make a difference for patients.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.

Pierre Fabre is a French health and beauty care company with 35-years of experience in innovation, development, manufacturing and commercialization in oncology. The company has recently reaffirmed oncology as one of its main R&D and commercial priorities, focusing on targeted therapies, biotherapies and immuno-oncology. Its therapeutic areas include unmet medical needs, and cover colorectal, breast, lung cancers, melanoma, pre-cancerous conditions such as actinic keratosis and EBV driven rare diseases. In 2021, Pierre Fabre generated €2.5 billion in revenues, 65% of which came from international sales.

Regeneron and Sanofi have collaborated since 2007 to develop fully-human monoclonal antibodies for the treatment of serious diseases, including cancer. Together, they are committed to advancing therapies that make a difference for patients.

Almirall is a global, research-focused biopharmaceutical company based in Barcelona. We invest in groundbreaking medical dermatology products to bring our innovative solutions to patients in need, with the help of our scientists based in our two R&D sites in Spain and Germany.The backbone of Almirall's activities is to guarantee the health and well-being of our patients, providing our experience and knowledge to design therapies adapted to their needs. We have carefully selected the skin conditions in which we are confident we can have the biggest impact by adding valuable solutions to improve the life of those patients living with them: psoriasis, actinic keratosis, atopic dermatitis, and acne.

Castle Biosciences is a leading diagnostics company that provides personalized, clinically actionable information to clinicians and patients to inform treatment decisions and improve health outcomes.The company is focused on transforming the disease management paradigm leveraging advanced technologies for its portfolio of innovative tests for skin cancers, uveal melanoma and Barrett’s esophagus. (www.CastleTestInfo.com)

Immunocore
Immunocore is a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Together, Merck KGaA, Darmstadt, Germany and Pfizer are dedicated to exploring innovative approaches to help improve treatment options for patients with cancer.

Together, Merck KGaA, Darmstadt, Germany and Pfizer are dedicated to exploring innovative approaches to help improve treatment options for patients with cancer.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

Canfield Scientific is the global leader in developing imaging systems for the medical and skin care industries. Used in hospitals,medical&aesthetic practices and skin care centers, Canfield’s advanced photographic imaging solutions are an integral part of consultations, built around a common patient image chart. From AI-driven iPad applications, to full-body 3D photography, thousands of surgical and non-surgical consultations begin with images captured by Canfield’s powerful imaging tools that improve communications, align doctor-patient expectations and facilitate treatment planning

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP- 001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com

Cook Biotech is dedicated to providing advanced tissue-repair products for improving patient outcomes globally. Products are manufactured using proprietary extracellular matrix (ECM) technologies and manufacturing processes. Through collaboration with partners and distributors, Cook Biotech products are available globally under several brand names including Biodesign® and OASIS®. Applications for ECM technology continually evolve. Together with a global network of scientists, partners, and medical practitioners, we continue to identify medical needs most compatible with ECM technology and develop products to meet those needs. Learn more about Cook Biotech at cookbiotech.eu

Damae Medical reinventing skin imaging, revolutionizing the screening, management, and follow-up of skin pathologies (such as melanoma, BCC, SCC, actinic keratosis etc.) with its deepLive™ solution, which provides an accurate, fast and reliable optical examination without performing a biopsy. CE marked, the deepLive™ medical device is based on LC-OCT (Line-field Confocal Optical Coherence Tomography) proprietary optical imaging technology that provides 3D images of the different layers of the skin at the cellular level, complemented by several software and Artificial Intelligence (AI) modules.

IGEA is the world leading company for Electrochemotherapy, a minimally invasive treatment combining a low dose of a chemotherapy drug and electrical pulses (electroporation) applied directly to the cancer cells using specific multiple or individual electrodes. Cliniporator® and Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located to the skin, subcutaneous tissue, parenchyma and bone.

IntraOp® is the leading innovator of electron therapy devices for treating cancer. IntraOp’s compact and mobile linear accelerators enable oncologists to deliver effective, precise, and affordable radiation therapy at the point of care. The Mobetron® has applications in intraoperative radiotherapy (IORT) and non-invasive treatment of skin cancer. The Mobetron is the first to offer ultra-high dose rate electron therapy for investigational studies of FLASH radiotherapy.

Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat cancer, autoimmune disorders, and chronic inflammatory conditions. We apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.

OncoBeta® is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta® has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium- SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. OncoBeta® has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Regeneron is a leading biotechnology company that invents life-transforming medicines for serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development. Visit www.Regeneron.com to learn more.

Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. We imagine a world where cancer is a curable disease.

SkylineDx develops molecular oncology tests for diagnostic, prognostic and predictive intended uses in collaboration with leading physicians, academic institutions, and industry partners around the world. SkylineDx aims at giving physicians the genomic tools to better guide the most effective treatment plan for their patients.

Speclipse, Inc., a medical device company founded by Stanford University graduates and a dermatologist, offers the world first cancer diagnostic solution based on Laser-Induced Plasma Spectroscopy (LIPS) and Artificial Intelligence (AI) Technology. The core product, Spectra-Scope® with CE mark and TGA approval, discovers Bio-Chemical information of skin tissue, providing instant, scar-free but highly accurate diagnosis for all types of skin cancer.

VivaScope GmbH, with headquarters and production in Munich, is a market specialist for the development and distribution of confocal laser scanning microscopes. This technology enables time-efficient tissue analysis that differentiates non-invasively and intra-operatively between pathogenic and healthy skin tissue.